Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 27, Issue 7, pp. 1850-1854
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 25, 2020
- Revision received October 8, 2020
- Accepted November 5, 2020
- Published first November 9, 2020.
Article Versions
- Previous version (November 9, 2020 - 06:00).
- Previous version (March 3, 2021 - 05:52).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Sakar Wahby1,*,
- Lola Fashoyin-Aje1,
- Christy L. Osgood1,
- Joyce Cheng1,
- Mallorie H. Fiero1,
- Lijun Zhang1,
- Shenghui Tang1,
- Salaheldin S. Hamed1,
- Pengfei Song1,
- Rosane Charlab1,
- Sarah E. Dorff1,
- Tiffany K. Ricks1,
- Kimberly Barnett-Ringgold1,
- Jeannette Dinin1,
- Kirsten B. Goldberg1,2,
- Marc R. Theoret1,2,
- Richard Pazdur1,2,
- Laleh Amiri-Kordestani1, and
- Julia A. Beaver1
- 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
- 2Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
- ↵*Corresponding Author:
Sakar Wahby, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Building 22, Room 2322, Silver Spring, MD 20993. Phone: 240-402-5364; E-mail: sakar.wahby{at}fda.hhs.gov
April 2021
Volume 27, Issue 7
Volume 27, Issue 7
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
Jump to section
Advertisement